These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22445654)

  • 1. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
    Pasero C; Speiser DE; Derré L; Olive D
    Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
    del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
    J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
    Murphy TL; Murphy KM
    Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.
    Steinberg MW; Cheung TC; Ware CF
    Immunol Rev; 2011 Nov; 244(1):169-87. PubMed ID: 22017438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
    Pasero C; Truneh A; Olive D
    Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14).
    Ware CF; Sedý JR
    Curr Opin Immunol; 2011 Oct; 23(5):627-31. PubMed ID: 21920726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model.
    Pierer M; Schulz A; Rossol M; Kendzia E; Kyburz D; Haentzschel H; Baerwald C; Wagner U
    J Immunol; 2009 Mar; 182(5):3139-45. PubMed ID: 19234211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.
    Pasero C; Barbarat B; Just-Landi S; Bernard A; Aurran-Schleinitz T; Rey J; Eldering E; Truneh A; Costello RT; Olive D
    Eur J Immunol; 2009 Sep; 39(9):2502-14. PubMed ID: 19701890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
    Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
    Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
    Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
    J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
    Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
    Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing co-stimulation and inhibition with BTLA and HVEM.
    Murphy KM; Nelson CA; Sedý JR
    Nat Rev Immunol; 2006 Sep; 6(9):671-81. PubMed ID: 16932752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
    Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
    Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.
    Chang YH; Hsieh SL; Chao Y; Chou YC; Lin WW
    J Biomed Sci; 2005; 12(2):363-75. PubMed ID: 15917993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
    Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A
    Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM].
    Pasero C; Olive D
    Bull Cancer; 2008; 95(7):691-700. PubMed ID: 18755648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.